Abstract
Continuous-flow left ventricular assist devices (CF-LVADs) have markedly improved outcomes in patients with heart failure. The HeartMate II (HM II) was the first CF-LVAD approved in the U.S. as a bridge to transplant (BTT) or as a definitive therapy (DT). However, LVAD thrombosis is a major complication associated with the use of these devices.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
Paper Title
Journal
Date
